Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial

Blood (2025) 146 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2025-1719

Published: 2025

Journal Articles

Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/ refractory (R/R) Acute Myeloid Leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial

Thomas Cluzeau, Pierre Yves Dumas, Pau Montesinos, Gaia Ciolli, Céline Berthon, Felicetto Ferrara, Adriano Venditti, José Antonio Pérez-Simón, Maria Calbacho, Richard Noppeney, Monia Lunghi, Chiara Cattaneo, Fabrizio Pane, Francesco Lanza, Juan Miguel Bergua Burgues, Alessandro Isidori, Yngvar Floisand, Vinay Jain, Eunice Wang

Blood (2025) 146 (Supplement 1): 767.

https://doi.org/10.1182/blood-2025-767

Published: 2025

Journal Articles

BMS-986397, a first-in-class casein kinase 1α (CK1α) degrader in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): A phase 1 dose escalation study

Blood (2025) 146 (Supplement 1): 1642.

https://doi.org/10.1182/blood-2025-1642

Published: 2025

Journal Articles

MO-TRANS update: A randomized, double-blind, placebo-controlled, multi-center phase III study of mocravimod (MOC) as maintenance treatment in AML patients undergoing allogeneic hematopoietic cell transplantation

Marcos de Lima, Gabriela Sanchez-Petitto, Edmund Waller, Charles Craddock, Maria Calbacho, Giancarlo Fatobene, Daniel Ghali, Jennifer Rubel, Stephan Oehen, Jens Hasskarl

Blood (2025) 146 (Supplement 1): 6086.

https://doi.org/10.1182/blood-2025-6086

Published: 2025

Journal Articles

Validation of the high-risk consensus genomic staging system in the era of bispecific antibodies: Role of NGS and cytogenetic reclassification

Maria Sanchez-Tabernero, Magdalena Corona, Cristian Gutiérrez Padilla, Jose Sanchez-Pina, Rafael Alonso, Inmaculada Rapado, Nieves Lopez-Muñoz, Gonzalo Carreño, Susana Cortijo, Maria Teresa Cedena Romero, Manuela Fernández, Rosa Ayala Diaz, Maria Calbacho, Joaquin Martinez-Lopez

Blood (2025) 146 (Supplement 1): 5781.

https://doi.org/10.1182/blood-2025-5781

Published: 2025

Journal Articles

Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3 -ITD Negative AML

Pau Montesinos, Rebeca Rodriguez-Veiga, Juan Miguel Bergua Burgues, Jesús Lorenzo Algarra, Carmen Botella, Eduardo Rodriguez Arboli, Teresa Bernal Del Castillo, Mar Tormo, Maria Calbacho, Olga Salamero, Josefina Serrano, Victor Noriega Concepcion, Juan Antonio Lopez Lopez, Susana Vives, Jose Luis Lopez Lorenzo, Mercedes Colorado, Maria Vidriales Vicente, Raimundo Garcia Boyero, Maria Teresa Olave Rubio, Pilar Herrera, Olga Arce, Manuel Barrios Garcia, Maria Jose Sayas Lloris, Marta Polo, Maria Isabel Gómez Roncero, Eva Barragán, Rosa Ayala, Carmen Chillon, Maria Jose Calasanz, Bruno Paiva, Blanca Boluda, Ignacio Casas Aviles, Pilar Lloret Madrid, María-José Sánchez-Sánchez, Carlos Rodríguez-Medina, Laida Cuevas Palomares, Jose Ángel Raposo Puglia, M Carmen Mateos Rodríguez, Matxalen Olivares Salaverri, Maria Del Carmen Martinez Chamorro, Natalia Alonso Vence, Sandra Suarez Ordoñez, Irene Sanchez Vadillo, María Solé-Rodríguez, Bernardo Javier González González, Antonio Martinez Frances, Rebeca Cuello, Alfonso Fernández Fernández, David Martinez-Cuadron, Jorge Labrador

Blood (2024) 144 (Supplement 1): 1512.

https://doi.org/10.1182/blood-2024-204779

Published: 2024

Journal Articles

A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Blood (2024) 144 (Supplement 1): 4986.

https://doi.org/10.1182/blood-2024-201407

Published: 2024

Journal Articles

Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 3565.

https://doi.org/10.1182/blood-2024-201944

Published: 2024

Journal Articles

Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3 -ITD-Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial

David Martinez-Cuadron, Rebeca Rodriguez-Veiga, Juan Miguel Bergua Burgues, Jesús Lorenzo Algarra, Carmen Botella, Jose Antonio Pérez-Simón, Teresa Bernal Del Castillo, Mar Tormo, Maria Calbacho, Olga Salamero, Josefina Serrano, Victor Noriega Concepcion, Juan Antonio Lopez Lopez, Susana Vives, Jose Luis Lopez Lorenzo, Mercedes Colorado, Maria Vidriales Vicente, Raimundo Garcia Boyero, Maria Teresa Olave Rubio, Pilar Herrera, Olga Arce, Manuel Barrios Garcia, Maria Jose Sayas Lloris, Marta Polo, Maria Isabel Gómez Roncero, Eva Barragán, Rosa Ayala, Carmen Chillon, Maria Jose Calasanz, Bruno Paiva, Blanca Boluda, Ignacio Casas Aviles, Pilar Lloret Madrid, Claudia Sargas, María-José Sánchez-Sánchez, Carlos Rodríguez-Medina, Laida Cuevas Palomares, Júlia Morán Sánchez, M Carmen Mateos Rodríguez, Matxalen Olivares Salaverri, Maria Del Carmen Martinez Chamorro, Natalia Alonso Vence, Sandra Suarez Ordonez, Irene Sanchez Vadillo, María Solé-Rodríguez, Bernardo Javier González González, Antonio Martinez Frances, Rebeca Cuello, Alfonso Fernández Fernández, Jorge Labrador, Pau Montesinos

Blood (2024) 144 (Supplement 1): 2895.

https://doi.org/10.1182/blood-2024-205064

Published: 2024

Journal Articles

Treatment with Siltuximab for Short Term Complications after Chimeric Antigen Receptor T-Cell Therapy: A Multicenter Retrospective Analysis

Jose M. Sanchez-Pina, Pablo Silva, Lucía López-Corral, Anabelle Chinea, Ana Africa Martin Lopez, Nuria Martinez-Cibrian, Rafael Hernani, Victor Noriega, Silvia Filaferro, Pascual Balsalobre, Maria Calbacho, Antonio Pérez-Martínez, Pere Barba, Mi Kwon

Blood (2024) 144 (Supplement 1): 7220.

https://doi.org/10.1182/blood-2024-207963

Published: 2024

Journal Articles

MO-TRANS: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Mocravimod (MOC) As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Gabriela Sanchez-Petitto, Maria Calbacho, Agata Wieczorkiewicz-Kabut, Malika Souquieres, Julien Cachat, Imene Henaoui, Daniel Ghali, Cristina Fernandez, Jeff Steinberg, Stephan Oehen, Christos Stylianou, Elisabeth Kueenburg, Marcos de Lima

Blood (2024) 144 (Supplement 1): 4952.1.

https://doi.org/10.1182/blood-2024-203080

Published: 2024

Journal Articles

Enhanced Validation of the FLT3 -like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial

Blood (2024) 144 (Supplement 1): 1552.

https://doi.org/10.1182/blood-2024-201264

Published: 2024

Journal Articles

Molecular Mechanisms of Quizartinib Response in FLT3-ITD Negative AML: An Updated Analysis from the Pethema Quiwi Trial

Blood (2024) 144 (Supplement 1): 6135.

https://doi.org/10.1182/blood-2024-201316

Published: 2024

Journal Articles

Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Pau Montesinos, Montserrat Arnan, Stephane De Botton, Maria Calbacho, Rebeca Rodriguez Veiga, Pierre Bories, Belén Ansoleaga, Thomas Hueso, Naval Daver, Lydia Wunderle, Andreas Harstrick, Kerstin Pietzko, Pallavi Hajela, Alexandra Vasile, Tania Witte, Elmarie Saenger, Christian Récher

Blood (2024) 144 (Supplement 1): 738.

https://doi.org/10.1182/blood-2024-194356

Published: 2024

Journal Articles

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Blood (2023) 142 (Supplement 1): 974.

https://doi.org/10.1182/blood-2023-180482

Published: 2023

Journal Articles

Trial in Progress: An Open Label Phase I/II, Multicenter Study Evaluating Safety, Pharmacokinetics and Efficacy of S65487, a BCL-2 Inhibitor Combined with Azacitidine in Adults with Previously Untreated Acute Myeloid Leukemia Ineligible for Intensive Treatment

Ana Alfonso Pierola, Stephane De Botton, Jun Ho Jang, Victoria Campbell, Jenny O'Nions, Maria Calbacho, Annette L. Ervin-Haynes, Kristen Keagle, Aline Maillard, Maud Beneton, Mathilde Romagnoli, Alberto Broniscer

Blood (2023) 142 (Supplement 1): 1555.

https://doi.org/10.1182/blood-2023-180795

Published: 2023

Journal Articles

Utility of Bone Marrow Biopsies for Basal Stratification and Response Assessment in a Large Series of Real Life Follicular Lymphoma Patients

Maria Poza Santaella, Rodrigo Íñiguez, Irene Zamanillo, Tycho S. Baumann, Antonia Rodriguez Izquierdo, Enrique Revilla, Sandra Gomez Rojas, Gloria Perez Segura, Pilar Martinez Sanchez, Carlos Grande, Pilar Sarandeses, Santiago Barrio, Maria Calbacho, Rosa Ayala, Joaquin Martinez-Lopez, Ana Jimenez Ubieto

Blood (2023) 142 (Supplement 1): 4405.

https://doi.org/10.1182/blood-2023-189161

Published: 2023

Journal Articles

Incidence, Management and Outcome of Post-Transplant Lymphoproliferative Disease after 5797 Solid-Organ Transplants over a 30-Year Period in a Single Hospital

Ana Jimenez Ubieto, Rodrigo Gil Manso, Daniel Gil Alós, María Poza Santaella, Tycho Baumann, Antonia Rodriguez Izquierdo, Marina Quesada Sánchez, Pilar Martinez Sanchez, Carlos Grande, Renata Garcia Gigorro, Maria Calbacho, Santiago Barrio, Joaquin Martinez Lopez

Blood (2023) 142 (Supplement 1): 4490.

https://doi.org/10.1182/blood-2023-189478

Published: 2023

Journal Articles

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Blood (2023) 142 (Supplement 1): 4883.

https://doi.org/10.1182/blood-2023-185858

Published: 2023

Journal Articles

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Blood (2023) 142 (Supplement 1): 6037.

https://doi.org/10.1182/blood-2023-180710

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial

Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/ refractory (R/R) Acute Myeloid Leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial

BMS-986397, a first-in-class casein kinase 1α (CK1α) degrader in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): A phase 1 dose escalation study

MO-TRANS update: A randomized, double-blind, placebo-controlled, multi-center phase III study of mocravimod (MOC) as maintenance treatment in AML patients undergoing allogeneic hematopoietic cell transplantation

Validation of the high-risk consensus genomic staging system in the era of bispecific antibodies: Role of NGS and cytogenetic reclassification

Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3 -ITD Negative AML

A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)

Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3 -ITD-Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial

Treatment with Siltuximab for Short Term Complications after Chimeric Antigen Receptor T-Cell Therapy: A Multicenter Retrospective Analysis

MO-TRANS: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Mocravimod (MOC) As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Enhanced Validation of the FLT3 -like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial

Molecular Mechanisms of Quizartinib Response in FLT3-ITD Negative AML: An Updated Analysis from the Pethema Quiwi Trial

Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Trial in Progress: An Open Label Phase I/II, Multicenter Study Evaluating Safety, Pharmacokinetics and Efficacy of S65487, a BCL-2 Inhibitor Combined with Azacitidine in Adults with Previously Untreated Acute Myeloid Leukemia Ineligible for Intensive Treatment

Utility of Bone Marrow Biopsies for Basal Stratification and Response Assessment in a Large Series of Real Life Follicular Lymphoma Patients

Incidence, Management and Outcome of Post-Transplant Lymphoproliferative Disease after 5797 Solid-Organ Transplants over a 30-Year Period in a Single Hospital

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only